| Market Capitalization (Millions $) |
24 |
| Shares
Outstanding (Millions) |
62 |
| Employees |
43 |
| Revenues (TTM) (Millions $) |
11 |
| Net Income (TTM) (Millions $) |
-139 |
| Cash Flow (TTM) (Millions $) |
21 |
| Capital Exp. (TTM) (Millions $) |
1 |
Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for psychiatric and neurological disorders. The company's lead product candidate, TNX-102 SL, is a sublingual tablet formulation of cyclobenzaprine being developed for the treatment of posttraumatic stress disorder (PTSD), fibromyalgia, and agitation in Alzheimer's disease. Tonix also has a pipeline of other product candidates targeting conditions such as migraine, cocaine dependence, and tick-borne diseases. The company utilizes a proprietary platform technology called Tonix Translational Medicine (TTM) to design new drug products with improved safety, efficacy, and pharmacokinetic properties.
Company Address: 26 Main Street Chatham 7928 NJ
Company Phone Number: 799-9155 Stock Exchange / Ticker: NASDAQ TNXP
|
